Close menu

May 23rd, 2024 | 08:30 CEST

E.ON, MGI - Media and Games Invest, Bayer - Through transformation into a golden future

  • renewableenergies
  • Pharma
  • Innovations
  • Digitization
  • Media
Photo credits:

Sometimes, companies are forced to overhaul their business areas if they wish to survive. A transformation is then unavoidable, and hopefully, the companies emerge stronger in the end. However, there is also the possibility that management will recognize the signs of the times early on and adapt their business models. From traditional companies that are starting a second life through digital innovation to young start-ups that are becoming market leaders through strategic realignments, companies are constantly facing challenges. Their path to a golden future is characterized by visionary decisions, agile adjustments and an unwavering will to improve continuously. We have selected three candidates that are currently undergoing a transformation.

time to read: 4 minutes | Author: Armin Schulz

Table of contents:

    E.ON - Decent quarterly figures

    E.ON has undergone a profound transformation in recent years. In the course of the energy transition and the associated move away from nuclear power and coal, the Company has redefined itself and realigned its strategy. This comprehensive change led to the splitting of the Group into two separate companies. The Company is now increasingly focusing on renewable energies, smart grids and customer solutions. The spun-off Uniper SE has taken over the conventional energy business, including gas and coal-fired power plants, as well as energy trading.

    On May 15, the Group announced its financial results for the first quarter, which met expectations. The adjusted EBITDA amounted to EUR 2.7 billion and was thus at the previous year's level. A significant increase in investments of almost 25% compared to the previous year to support further growth was highlighted. The Group's financial basis remains solid thanks to the successful placement of bonds worth EUR 3.3 billion to cover the financial requirements for the current year. The forecast remains optimistic, with a targeted adjusted EBITDA of between EUR 8.8 and 9.0 billion and an expected adjusted Group net profit of EUR 2.8 to 3.0 billion.

    Given the increased investment activity and the confirmed financial forecast for 2024, E.ON remains focused on consistently driving forward the energy transition. With the newly created Energy Infrastructure Solutions business area, the Company is also focusing on a transparent presentation of its growth potential. Despite the increased investments and the resulting negative impact on operating cash flow and net debt, E.ON is signaling stability and a positive anticipation of future developments. The share fell after the figures, partly due to the dividend paid, and is currently trading at EUR 12.60.

    MGI - From games manufacturer to advertising company

    MGI - Media and Games Invest (MGI) has undergone an impressive transformation since its restructuring and acquisition of gamigo in 2012. Originally launched as a gaming company, MGI significantly expanded its business activities in 2018 to include the media sector and entered the advertising business. This strategic realignment has enabled the Company to establish a strong market position through a combination of acquisitions and organic growth. Today, the Company owns an advanced programmatic advertising platform that auctions ads on various digital channels in real-time.

    The Company relies on artificial intelligence and detailed data analytics to deliver personalized advertising that is relevant to both advertisers and users. The ads are displayed on websites, mobile devices, and connected TV advertising. This gives MGI a competitive advantage in a dynamic market environment where precise and targeted advertising is becoming increasingly important. Despite challenging economic conditions, such as the impact of the Ukraine conflict and rising interest rates, MGI reported impressive financial figures for the first quarter.

    Revenue increased by 20% to EUR 82.5 million, with organic revenue rising by as much as 21%. Adjusted EBITDA grew by 16% to EUR 22 million. This growth is mainly due to the increase in the customer base and efficiency gains through process savings. The Company has an optimistic outlook for 2024 as a whole, with expected revenue of between EUR 350 million and EUR 370 million and adjusted EBITDA of EUR 100 million to EUR 110 million. At the upcoming Annual General Meeting on June 13, the transformation into a fast-growing digital media company is to be finalized by renaming the Company "Verve". Since the announcement of the annual figures, the share price has recovered significantly from its low for the year of EUR 0.77 and is currently trading at EUR 1.716.

    Bayer - Undergoing a transformation

    Bayer's acquisition of Monsanto in 2018 marked a turning point in the Company's history and made Bayer one of the most prominent players in the agricultural sector. The acquisition significantly expanded Bayer's agricultural business, making it a leading supplier of seeds and crop protection products worldwide. While Bayer strengthened its market position by integrating Monsanto's product portfolio, including genetically modified seeds and glyphosate, it also took on legal risks and image problems. However, the legal disputes ultimately led to difficulties for the Company.

    Bayer presented its quarterly figures on May 14, 2024, and triggered mixed feelings among investors. Revenue fell 4.3 % to EUR 13.8 billion compared to the previous year. However, the decline was only 0.6% when adjusted for currency effects and portfolio adjustments. At the same time, EBIT increased by 4.0% to EUR 3.1 billion, while diluted earnings per share fell from EUR 2.22 to EUR 2.04. Despite a continued negative free cash flow, this showed an improvement, falling from minus EUR 4.1 billion in the previous year to minus EUR 2.6 billion. The new drugs Nubeqa and Kerendia are particularly in focus.

    Nubeqa, a drug for the treatment of prostate cancer, achieved an impressive sales growth of 64% to EUR 283 million. Kerendia, a drug for chronic kidney disease, recorded sales growth of 66% to EUR 85 million. Analysts see significant growth potential in these drugs, particularly in the expanded use of Kerendia in other indications such as heart failure. This could cushion the upcoming patent losses for blockbuster drugs. The quarterly figures briefly lifted the share back above the EUR 30 mark. The current price per share is EUR 28.00.

    Transformations can have positive effects on companies. In the energy sector, E.ON has created a solid basis for future growth through a strategic realignment and considerable investments in renewable energies and intelligent grids. MGI - Media and Games Invest has successfully transformed itself from a game developer into a major player in the digital advertising business and has recently impressed with its financial results. Despite the challenges posed by acquiring Monsanto and the associated legal disputes, Bayer has strengthened its position in the market through innovative medicines and adjustments to its business model. However, the transformation is still ongoing.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a "Transaction"). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
    In this respect, there is a concrete conflict of interest in the reporting on the companies.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
    For this reason, there is also a concrete conflict of interest.
    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author

    Related comments:

    Commented by Fabian Lorenz on June 12th, 2024 | 07:00 CEST

    Shock at Plug Power! Thyssenkrupp Nucera and Altech Advanced Materials with up to 100% upside potential!

    • Batteries
    • Hydrogen
    • Innovations

    Alarm at Plug Power. After the price jump in May, the share has gone into reverse again and lost 10% of its value in just a few days. Financing worth billions for the struggling hydrogen pioneer is uncertain, bringing the Company's potential insolvency back into the focus of investors. German hydrogen hopeful Thyssenkrupp Nucera received positive analyst comments. Could the share perhaps even double in value? And what is Altech Advanced Materials doing? The shares of the German battery hopeful have bottomed out and may offer an entry opportunity. The market potential for Altech is huge.


    Commented by André Will-Laudien on June 11th, 2024 | 06:45 CEST

    After the European elections: Is it all happening now? Nel ASA, Kraken Energy, Siemens Energy, ThyssenKrupp and Nucera in focus

    • Mining
    • Uranium
    • renewableenergies
    • Energy

    Europe has voted, and the Green parties have suffered historic losses! Now, the energy debate is coming to the fore again. While Germany is focusing entirely on green energy in the future, other countries have long since turned the challenges of the time into action. Nuclear energy remains a "zero-zero solution", making France, the Czech Republic and Poland the biggest climate protection exporters in the EU. This is because many new state-of-the-art reactors are being built here. The electricity market is huge, as Germany alone will have to shut down its gas and coal-fired power plants over the next few years due to the CO2 reduction commitments from the Paris Agreement. This threatens to create a supply gap that can only be filled with alternative energies, nuclear power, or hydrogen. What should investors focus on now?


    Commented by Armin Schulz on June 10th, 2024 | 07:15 CEST

    Evotec, Vidac Pharma, Bayer - Biotech and Pharma: Opportunities for investors

    • Biotechnology
    • Pharma

    In the constantly evolving pharmaceutical and biotechnology industry landscape, innovative strength and strategic orientation play a decisive role in success. Both established groups and young, up-and-coming companies are competing for market share and scientific breakthroughs. In this context, it is worth taking a closer look at Vidac Pharma, Bayer and Evotec. These companies are pursuing different approaches and strategies to achieve their respective goals. How do they manage to hold their own in a highly dynamic market environment, and what prospects are emerging for the future?